920113-01-5

Upstream product

• 610-96-8 methyl chlorobenzoate 
• 117955-09-6 (±)-trans-[1-methyl-3-(2,4,6-trimethoxyphenyl)pyrrolidin-2-yl]methanol 
• 920112-97-6 (-)-trans-[1-methyl-3-(2,4,6-trimethoxyphenyl)pyrrolidin-2-yl]methanol 
• 1254504-57-8 C₁₅H₂₃NO₄*C₁₈H₁₄O₈ 
• 609-65-4 o-chlorobenzoyl chloride 
• 118-91-2 ortho-chlorobenzoic acid 
• 920112-99-8 ((-)-trans-acetic acid-3-(3-acetyl-2-hydroxy-4,6-dimethoxyphenyl)-1-methylpyrrolidin-2-yl)methyl ester 
• 1622998-49-5 (-)-trans-2-(2-(acetoxymethyl)-1-methylpyrrolidin-3-yl)-6-acetyl-3,5-dimethoxyphenyl-2-chlorobenzoate 
• 113225-07-3 1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydropyridine 
• 621-23-8 1,2,3-trimethoxybenzene 
• 113225-08-4 (±)-trans-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidin-3-ol 
• 920113-00-4 (-)-trans-1-[2-hydroxy-3-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-4,6-dimethoxyphenyl]-ethanone 

Downstream Products

• 920113-02-6 (+)-trans-2-(2-chloro-phenyl)-5,7-dihydroxy-8-(2-hydroxymethyl-1-methyl-pyrrolidin-3-yl)-chromen-4-one 
• 920113-03-7 (+)-2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2R,3S)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]-4H-chromen-4-one hydrochloride 

Relevant academic research and scientific papers

A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA

The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agen

AN IMPROVED PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES

The present invention relates to a process for the preparation of a key intermediate (as described herein) used in the synthesis of (+)-trans enantiomer of pyrrolidine substituted flavones, represented by the compounds of formula (1) or pharmaceutically a

A PROCESS FOR PREPARATION OF AN INTERMEDIATE OF THE PYRROLIDINE SUBSTITUTED FLAVONES

The present invention relates to a process for the preparation of a key intermediate (as described herein) used in the synthesis of (+)-trans enantiomer of pyrrolidine substituted flavones, represented by the compounds of formula (1) or pharmaceutically a

AN ENANTIOSELECTIVE SYNTHESIS OF PYRROLIDINE-SUBSTITUTED FLAVONES

The present invention relates to an enantioselective synthesis of (+)-trans enantiomer of pyrrolidines substituted with flavones, represented by Formula 1 or salts thereof, which are inhibitors of cyclin dependant kinases and can be used for treatment of